Learn More
In tumour lysis syndrome (TLS), metabolic alterations caused by the destruction of malignant cells manifest as laboratory abnormalities with (clinical TLS) or without (laboratory TLS) organ(More)
Azacitidine (AZA) is the current frontline standard of care regimen for patients with higher-risk myelodysplastic syndromes (MDS) in Europe (Fenaux et al, 2009). However, hypomethylating agents(More)
  • 1